Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit
一项评估厄洛替尼±奥那妥珠单抗治疗晚期非小细胞肺癌的安慰剂对照 II 期研究的生物标志物分析：MET 表达水平可预测患者获益
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-13-1836
Hartmut Koeppen, Wei Yu, Jiping Zha, Ajay Pandita, Elicia Penuel, Linda Rangell, Rajiv Raja, Sankar Mohan, Rajesh Patel, Rupal Desai, Ling Fu, An Do, Vaishali Parab, Xiaoling Xia, Tom Januario, Sharianne G Louie, Ellen Filvaroff, David S Shames, Ignacio Wistuba, Marina Lipkind, Jenny Huang, Mirella
